Immunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event
Immunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 13
th Annual Biotech Showcase Digital Event, January 11-15, 2021. Chief Executive Officer at ITI, Dr. Bill Hearl, will present a talk titled, ITI-1000-A Novel Immunotherapy for GBM. Dr. Hearl will discuss ITIs investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology, specifically glioblastoma multiforme (GBM). ITIs technology platform has the potential to utilize the bodys natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.